Just over a year ago, there was a major breakthrough in Parkinson’s disease (PD) research – the discovery of a tool that could detect abnormal alpha-synuclein protein in the spinal fluid of people living with PD even before onset of symptoms. The breakthrough is already impacting the ways scientists who study Parkinson’s conduct research and think about the disease. Tune into this episode of our award-winning “Parkinson’s Science POV” series to learn how they are using the tool to better understand disease biology and what the future holds.
If you’d rather listen on the go, subscribe to our Michael J. Fox Foundation Parkinson’s Podcast on iTunes or through any podcast app on your smartphone or tablet. If you enjoyed what you heard, share it with a friend or leave a review on iTunes. It helps listeners like you find and support our mission.
Join Maggie Kuhl, vice president of research engagement at The Michael J. Fox Foundation (MJFF), as she leads a discussion about the ways the biomarker discovery helps reveal connections with other brain diseases and holds the promise to make clinical trials cheaper, faster and more effective. Our two expert panelists are:
-
Brian Fiske, PhD, MJFF co-chief science officer
-
Mark Frasier, PhD, MJFF co-chief science officer
View a transcript of this podcast.
Whether you have Parkinson’s or not, you can help move research forward. Join the study that’s changing everything.